Morgan Stanley raised the firm’s price target on CG Oncology (CGON) to $56 from $52 and keeps an Overweight rating on the shares. Even with recent and anticipated approvals in the non-muscle invasive bladder cancer space, the firm believes the bladder cancer landscape is large enough for multiple players and it views cretostimogene as having “best-in-disease potential” and meaningfully differentiated by its durability and safety data, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology Holds 2025 Annual Stockholders Meeting
- Promising Market Position and Investment Opportunity: CG Oncology’s Creto in NMIBC Treatment
- CG Oncology Advances Bladder Cancer Therapies in Q1 2025
- Promising Outlook for CG Oncology: Strong Financial Health and Positive Trial Results for Cretostimogene
- CG Oncology, Inc.: Promising Outlook with Strong Clinical Performance and Strategic BLA Submission